無料プレビュー

Kiniksa Pharmaceuticals International, plc (KNSA) · NASDAQ

プロフィール

Kinikska Pharmaceuticals International, plc is a biopharmaceutical company developing and commercializing novel therapies for cardiovascular and inflammatory diseases with unmet medical need. The company markets ARCALYST, an IL-1α and IL-1β cytokine trap approved for recurrent pericarditis and other inflammatory conditions, and is advancing clinical-stage candidates KPL-387 and KPL-1161 targeting IL-1 signaling, as well as abiprubart targeting CD40-CD154 interaction. The company operates in the United States and internationally through direct commercialization and partnerships including licens

主要指標

株価: $78.75 (+1.01%)
時価総額: 60億ドル
PER（今期予想）: 56.5
PBR: 9.3
配当利回り: —
52週レンジ: $35.20 – $82.94
業種: Healthcare / Medical - Pharmaceuticals
上場: NASDAQ
構成銘柄: —

比較会社: RPRX Royalty Pharma plc、CORT Corcept Therapeutics Incorporated、WBA Walgreens Boots Alliance, Inc.、SYRE Spyre Therapeutics, Inc.、IMVT Immunovant, Inc.、ORKA Oruka Therapeutics, Inc.、DNTH Dianthus Therapeutics, Inc.、LQDA Liquidia Corporation

長期トレンド・直近動向・強気／弱気シナリオ・業績10年・バリュエーション・テクニカル・株主・役員・深掘り分析は会員向けです。

7日間無料で全文を読むログイン

次回決算: 2026-10-27 · 更新: 2026-10-09